Cough Hypersensitivity Syndrome Global Market Report 2024

The global cough hypersensitivity syndrome market has grown strongly in recent years. It will grow from $9.71 billion in 2023 to $10.36 billion in 2024 at a compound annual growth rate (CAGR) of 6.8%. The growth in the historic period can be attributed to increased awareness, telemedicine and remote monitoring, public health initiatives, research funding.

The global cough hypersensitivity syndrome market is expected to see strong growth in the next few years. It will grow to $13.51 billion in 2028 at a compound annual growth rate (CAGR) of 6.9%. The growth in the forecast period can be attributed to global health access, patient advocacy and support, quality of life improvements. Major trends in the forecast period include improved diagnosis and screening tools, personalized treatment approaches, new medications.

The increasing prevalence of chronic respiratory diseases is anticipated to be a significant driver for the growth of the cough hypersensitivity syndrome market in the coming years. Chronic respiratory diseases (CRDs) encompass a range of long-term conditions affecting the airways and lungs, resulting in ongoing breathing difficulties and a gradual decline in lung function. Treatment for cough hypersensitivity syndrome aims to alleviate discomfort and improve respiratory health, ultimately enhancing the quality of life for individuals grappling with chronic respiratory conditions like asthma. For instance, as of June 2023, the Australian Institute of Health and Welfare reports that nearly 30% of the Australian population, equivalent to 7.5 million individuals, are contending with chronic respiratory diseases. Furthermore, in the same period, the Centers for Disease Control and Prevention noted 142,342 deaths attributed to chronic lower respiratory diseases in 2021 in the United States. Consequently, the growing prevalence of chronic respiratory diseases serves as a driving force behind the expansion of the cough hypersensitivity syndrome market.

The increasing population of cigarette smokers is anticipated to be a significant factor propelling the expansion of the cough hypersensitivity syndrome market in the foreseeable future. Cigarette smokers are individuals who regularly engage in tobacco use by smoking cigarettes, involving the inhalation of smoke generated from burning tobacco leaves encased in a paper-wrapped cylinder. Cigarette smoking induces cough hypersensitivity syndrome by provoking irritation in the airways, inciting inflammation, and causing damage to lung tissues. For instance, as of July 2022, Statistics Canada reported a 5.8% increase in cigarette production compared to June 2021. Additionally, the total number of cigarettes sold rose by 1.3%, reaching 1.4 billion in June 2022. Furthermore, in May 2023, the Centers for Disease Control and Prevention revealed that an estimated 28.3 million U.S. adults are cigarette smokers, with about 3.08 million U.S. middle and high school students using at least one tobacco product. Each day, approximately 1,600 U.S. youth under the age of 18 try their first cigarette. Therefore, the growing population of cigarette smokers is expected to drive the growth of the cough hypersensitivity syndrome market.

Drug abuse is anticipated to have an adverse effect on the growth of the cough hypersensitivity syndrome market in the coming years. The misuse of these substances can lead to dependency, abuse, or the occurrence of central side effects. While drugs like morphine and diamorphine can be highly effective in alleviating severe and distressing coughs in patients with terminal illnesses such as cough hypersensitivity syndrome, they also carry a risk of addiction. For instance, as of June 2022, Springer Nature Limited reported an increase in the use of antitussive agents for cough hypersensitivity syndrome. Some of these agents, including codeine and hydrocodone, belong to the opioid class of drugs, which have the potential to lead to addiction and substance use disorder. Consequently, drug abuse is expected to negatively impact the growth of the cough hypersensitivity syndrome market.

Leading companies in the cough hypersensitivity syndrome market are embracing AI-powered algorithms to drive innovation and maintain their competitive edge. These algorithms harness the power of artificial intelligence (AI) to execute tasks and tackle challenges in an efficient and effective manner. For instance, in April 2021, NuvoAir, a US-based digital healthcare company, unveiled the NuvoAir Cough mobile application designed for detecting cough hypersensitivity syndrome. This innovative smartphone app is compatible with the iOS operating system and employs the device's microphone along with an AI-powered algorithm to discern and record coughs within domestic environments. The algorithm distinguishes coughs from other ambient sounds, providing the results to both the user and their attending physician.

In June 2023, GlaxoSmithKline PLC, a prominent UK-based pharmaceutical and biotechnology company specializing in the production of drugs for cough hypersensitivity syndrome, completed the acquisition of Bellus Health Inc. for $2.0 billion. Through this strategic move, GSK aims to bolster its array of respiratory medications, as well as enhance its capabilities in research and development, production, and commercialization. Bellus Health Inc. is a biotechnology company based in Canada, known for its development of drugs tailored for cough hypersensitivity syndrome.

Major players in the cough hypersensitivity syndrome market are Pfizer Inc., Johnson and Johnson Ltd., F. Hoffmann-La Roche AG, Bayer AG, Novartis AG, Merck and Co Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca Plc., GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim GmbH, Wyeth Pharmaceuticals Inc., AstraZeneca Pharmaceuticals LP, Teva Pharmaceutical Industries Ltd., Mylan N.V., Lupin Limited, Cadila Pharmaceuticals, Almirall S.A., Akorn Operating Company LLC, Kudco Ireland Ltd., Prestige Consumer Healthcare Inc., GMP Laboratories of America Inc., The Betty Mills Company, Acura Pharmaceuticals Inc.

North America was the largest region in the cough hypersensitivity syndrome market in 2023. The regions covered in cough hypersensitivity syndrome report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the cough hypersensitivity syndrome market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The main drug types used for treating cough hypersensitivity syndrome include inhaled corticosteroids, antitussive agents, short-acting beta-2 agonists, anticholinergics, proton pump inhibitors, antihistamines, and others. Inhaled corticosteroids (ICS) refer to a class of medications used in the treatment of various respiratory conditions. These drugs can be administered orally, through inhalation, or by other means. They are utilized by various end-users, including hospitals, specialty clinics, homecare services, and others.

This report provides cough hypersensitivity syndrome market statistics, including cough hypersensitivity syndrome industry global market size, regional shares, competitors with a cough hypersensitivity syndrome market share, detailed cough hypersensitivity syndrome market segments, market trends and opportunities and any further data you may need to thrive in the cough hypersensitivity syndrome industry. This cough hypersensitivity syndrome market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cough hypersensitivity syndrome market consists of sales of cough suppressants, steam inhalers and humidifiers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.